ImmunityBio (IBRX) Other Operating Expenses (2014 - 2026)
ImmunityBio (IBRX) posted quarterly Other Operating Expenses of -$236.6 million for Q1 2026, down 455.69% year-over-year from $66.5 million in Q1 2025, and down 123787.43% quarter-over-quarter from -$191000.0 in Q4 2025.
ImmunityBio (IBRX) Other Operating Expenses (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported Other Operating Expenses for 9 consecutive years, with -$236.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Operating Expenses fell 455.69% year-over-year to -$236.6 million; the TTM figure through Mar 2026 stood at -$236.8 million (down 26708.54% YoY), while the FY2025 annual figure was -$42.8 million, down 198.39% from the prior year.
- Other Operating Expenses retreated to -$236.6 million in Q1 2026 per IBRX's latest filing, from -$191000.0 in the prior quarter.
- Across five years, Other Operating Expenses topped out at $43.5 million in Q4 2024 and bottomed at -$236.6 million in Q1 2026.
- Historically, Other Operating Expenses has averaged -$30.2 million across 4 years, with a median of -$1.2 million in 2025.
- Annual changes were most pronounced in 2024 — Other Operating Expenses surged 217.64% — and 2026, when it tumbled 455.69%.
- ImmunityBio's Other Operating Expenses stood at -$37.0 million in 2023, then soared by 217.64% to $43.5 million in 2024, then plunged by 100.44% to -$191000.0 in 2025, then slumped by 123787.43% to -$236.6 million in 2026.
- Business Quant data shows IBRX's Other Operating Expenses at -$236.6 million in Q1 2026, -$191000.0 in Q4 2025, and -$1.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | ImmunityBio | 7.97 Bn | 7.62 Bn | 50.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -95.96 Mn |
| Mar 31, 2026 | -236.63 Mn |
| Dec 31, 2025 | -191,000.00 |
| Sep 30, 2025 | -1.17 Mn |
| Jun 30, 2025 | 1.17 Mn |
| Mar 31, 2025 | -42.58 Mn |
| Dec 31, 2024 | 43.47 Mn |
| Dec 31, 2023 | -36.95 Mn |
| Sep 30, 2023 | 7.52 Mn |
| Jun 30, 2023 | -6.77 Mn |
| Dec 31, 2020 | -36.33 Mn |
| Sep 30, 2020 | 10.66 Mn |
| Dec 31, 2019 | -90.60 Mn |
| Dec 31, 2016 | 7.44 Mn |
| Dec 31, 2015 | 2.10 Mn |
| Mar 31, 2014 | 120,000.00 |